Mind Medicine (MindMed) Inc.
MNMD
Price:
$7.56
Market Cap:
$554.39M
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.[Read more]
Industry
Biotechnology
IPO Date
2016-11-15
Stock Exchange
NASDAQ
Ticker
MNMD
PE Ratio
[-4.42]
ROE
[-52.98%]
Current Ratio
[9.00]
Dividend Yield
[0%]
Enterprise Value
[283.41M]
Dividend History
The ROE as of November 2024 (TTM) for Mind Medicine (MindMed) Inc. (MNMD) is -52.98%
According to Mind Medicine (MindMed) Inc.’s latest financial reports and current stock price. The company's current ROE is -52.98%. This represents a change of 219.12% compared to the average of -16.60% of the last 4 quarters.
Mind Medicine (MindMed) Inc. (MNMD) Historical ROE (quarterly & annually)
How has MNMD ROE performed in the past?
The mean historical ROE of Mind Medicine (MindMed) Inc. over the last ten years is -58.92%. The current -52.98% ROE has changed -10.08% with respect to the historical average. Over the past ten years (40 quarters), MNMD's ROE was at its highest in in the December 2022 quarter at 2.71%. The ROE was at its lowest in in the December 2021 quarter at -61.34%.
Average
-58.92%
Median
-40.75%
Minimum
-141.34%
Maximum
-24.34%
Mind Medicine (MindMed) Inc. (MNMD) ROE by Quarter and Year
Discovering the peaks and valleys of Mind Medicine (MindMed) Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 333.49%
Maximum Annual ROE = -24.34%
Minimum Annual Increase = -78.01%
Minimum Annual ROE = -141.34%
| Year | ROE | Change |
|---|---|---|
| 2023 | -122.52% | 291.25% |
| 2022 | -31.32% | -48.95% |
| 2021 | -61.34% | 36.48% |
| 2020 | -44.95% | 10.29% |
| 2019 | -40.75% | 67.43% |
| 2018 | -24.34% | -21.68% |
| 2017 | -31.08% | -78.01% |
| 2016 | -141.34% | 333.49% |
Mind Medicine (MindMed) Inc. (MNMD) Average ROE
How has MNMD ROE performed in the past?
The current ROE of Mind Medicine (MindMed) Inc. (MNMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-71.73%
5-year avg
-60.18%
10-year avg
-58.92%
Mind Medicine (MindMed) Inc. (MNMD) ROE vs. Peers
How is MNMD’s ROE compared to its peers?
Mind Medicine (MindMed) Inc.’s ROE is greater than Cybin Inc. (-52.19%), greater than Seelos Therapeutics, Inc. (-13.07%), greater than GH Research PLC (-20.29%), less than Awakn Life Sciences Corp. (175.85%), greater than Atai Life Sciences N.V. (-66.03%), greater than Freeline Therapeutics Holdings plc (-77.99%), less than Bio-Path Holdings, Inc. (2.62%), less than Vaccinex, Inc. (1.93%), greater than Eliem Therapeutics, Inc. (-47.03%), less than Opthea Limited (360.15%), greater than Molecular Partners AG (-39.16%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than iTeos Therapeutics, Inc. (-20.11%), less than Checkpoint Therapeutics, Inc. (359.97%), less than Mustang Bio, Inc. (429.53%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Fortress Biotech, Inc. (-240.30%), greater than Kodiak Sciences Inc. (-84.52%),
| Company | ROE | Market cap |
|---|---|---|
| -52.19% | $196.32M | |
| -13.07% | $214.97K | |
| -20.29% | $482.30M | |
| 175.85% | $3.95M | |
| -66.03% | $270.16M | |
| -77.99% | $28.28M | |
| 2.62% | $3.53M | |
| 1.93% | $9.41M | |
| -47.03% | $342.68M | |
| 360.15% | $486.27M | |
| -39.16% | $219.11M | |
| -26.83% | $3.05B | |
| -20.11% | $303.96M | |
| 359.97% | $180.50M | |
| 429.53% | $9.63M | |
| 664.92% | $38.12M | |
| -240.30% | $44.44M | |
| -84.52% | $325.74M |
Build a custom stock screener for Mind Medicine (MindMed) Inc. (MNMD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mind Medicine (MindMed) Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Mind Medicine (MindMed) Inc. (MNMD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Mind Medicine (MindMed) Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Mind Medicine (MindMed) Inc.'s ROE?
How is the ROE calculated for Mind Medicine (MindMed) Inc. (MNMD)?
What is the highest ROE for Mind Medicine (MindMed) Inc. (MNMD)?
What is the 3-year average ROE for Mind Medicine (MindMed) Inc. (MNMD)?
What is the 5-year average ROE for Mind Medicine (MindMed) Inc. (MNMD)?
How does the current ROE for Mind Medicine (MindMed) Inc. (MNMD) compare to its historical average?